This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ICAD Reports Growing Adoption And Utilization Of Its Xoft System For Breast And Skin Cancers

iCAD, Inc. (Nasdaq: ICAD), a leading provider of advanced imaging and radiation therapy for the early identification and treatment of cancer, today announced growing demand, adoption and clinical evidence for its Xoft® Axxent® Electronic Brachytherapy System® for the treatment of early-stage breast cancer and non-melanoma skin cancer.

“We are seeing significant growth in our radiation therapy business across multiple therapeutic areas, active enrollment in post-market studies and a growing body of clinical data in support of the Xoft System, all of which are driving momentum for the company,” said Ken Ferry, President and CEO of iCAD. “The use of our system to treat non-melanoma skin cancer continues to expand rapidly, evidenced by more than 3,000 patients treated to date using the Xoft System, the only electronic brachytherapy system with peer-reviewed published data for this application.”

Leading Medical Centers Adopt the Xoft System

Some of the latest medical centers to adopt the Xoft System include City of Hope (Duarte, Calif.), Staten Island University Hospital (Staten Island, NY), Strimling Dermatology, Laser & Vein Institute (Las Vegas, Nev.), Mobile Skin Cancer Radiation Specialists (Phoenix, Ariz.) and University of Oklahoma Breast Institute (Oklahoma City, Okla.)

Growing Clinical Evidence

A prospective, multi-center, clinical trial evaluating the safety, efficacy and cosmetic outcomes associated with Intraoperative Radiation Therapy (IORT) for early-stage breast cancer with the Xoft System, continues to gain momentum. To date, 19 medical centers across the U.S. have enrolled more than 180 patients.

“The Xoft System allows us to offer our patients with early-stage breast cancer an advanced treatment option that eliminates many of the burdens commonly associated with post-surgical radiation treatment,” said Laura Kruper, M.D., Breast Surgeon and Director of the Rita Cooper Finkel and J. William Finkel Women’s Health Center at City of Hope Hospital. “The Xoft System delivers a full course of radiation therapy at the time of lumpectomy surgery, minimizing exposure to surrounding healthy tissue and organs and replacing weeks of follow up treatment with just one dose.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs